ConductScience.org, home

Trial · NCT05803642

A Study of Olanzapine in Patients With Acute Agitation

NCT05803642, Phase 3, Unknown, Qilu Pharmaceutical Co., Ltd.

3 sourcestrials-2026-11-12-0.4.0

Download JSON
Cite this record

ConductScience Library. A Study of Olanzapine in Patients With Acute Agitation. Trials, record NCT05803642. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05803642

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
A Study of Olanzapine in Patients With Acute Agitation
NCT number
NCT05803642
Status
Unknown
Phases
Phase 3
Enrollment
318 participants, estimated
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
Conditions
Acute Agitation
Interventions
Olanzapine, Haloperidol
First posted
2023-04-07
Last updated
2023-04-07

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChange from baseline to 2 hours post-first IM injection on the PANSS-EC2 hours
The PANSS-EC comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
SecondaryPercentage of Participants With 40% or Greater Percent Decrease in the PANSS-EC Total Score2 hours post-first IM injection
SecondaryProportion of participants receiving one, two, or three doses of study drug during 24-hour intramuscular treatment period24 hours

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMIDListed as
41778148DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release
trials-2026-11-12-0.4.0
Release manifest SHA-256
0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture
2026-11-12
Results copy, AACT
2026-03-23
NIH clinical studies file
2026-11-13

Source ClinicalTrials.gov

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05803642

GET https://conductscience.org/api/trials/v1/NCT05803642/registered